OS Therapies (OSTX) files 8-K/A to add Leonite Fund side letter exhibit
Filing Impact
Filing Sentiment
Form Type
8-K/A
Rhea-AI Filing Summary
OS Therapies Incorporated filed an amendment to a prior current report to add a missing exhibit related to a previously disclosed private placement. The amendment, dated June 30, 2026, attaches a side letter between OS Therapies and Leonite Fund I, LP as Exhibit 10.3.
The original report, filed on July 2, 2026, had already described the private placement and included the main agreements such as the senior secured convertible promissory note, securities purchase agreement, and pledge and security agreement by reference. This amendment does not change any of those disclosures and should be read together with the original filing.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 9.01 — Financial Statements and Exhibits
1 item
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Amendment date: June 30, 2026
Original report filing date: July 2, 2026
New exhibit added: Exhibit 10.3
+2 more
5 metrics
Amendment date
June 30, 2026
Date of Amendment No. 1 and related side letter
Original report filing date
July 2, 2026
Date of original current report on private placement
New exhibit added
Exhibit 10.3
Side Letter between OS Therapies and Leonite Fund I, LP
Convertible note form
Exhibit 4.1
Form of Senior Secured Convertible Promissory Note
Warrant form
Exhibit 4.2
Form of Common Stock Purchase Warrant
Key Terms
Senior Secured Convertible Promissory Note, Common Stock Purchase Warrant, Securities Purchase Agreement, Pledge and Security Agreement, +1 more
5 terms
Senior Secured Convertible Promissory Note financial
"Form of Senior Secured Convertible Promissory Note (incorporated by reference to Exhibit 4.1..."
A senior secured convertible promissory note is a formal IOU a company issues that is backed by specific assets (secured), given higher priority for repayment than other debts (senior), and can be exchanged for company shares instead of cash (convertible). For investors this means the loan is safer than unsecured debt because it has collateral and repayment priority, but it also carries the potential for dilution if the lender converts the note into equity — like holding a mortgage-backed IOU that can later be swapped for ownership stakes.
Common Stock Purchase Warrant financial
"Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2..."
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
Securities Purchase Agreement financial
"Securities Purchase Agreement, dated as of June 30, 2026, among OS Therapies Incorporated..."
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Pledge and Security Agreement financial
"Pledge and Security Agreement, dated as of June 30, 2026, among OS Therapies Incorporated..."
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What is OS Therapies (OSTX) changing in this 8-K/A filing?
OS Therapies is filing an amendment solely to add Exhibit 10.3, a side letter dated June 30, 2026 with Leonite Fund I, LP, which was inadvertently omitted from the original current report on the private placement.
Does this OS Therapies (OSTX) 8-K/A alter the original private placement terms?
The amendment does not change the original private placement disclosures. It only adds the missing side letter as Exhibit 10.3, and explicitly states that all other information from the original report remains unchanged and should be read together.
Which new exhibit is included in the OS Therapies (OSTX) 8-K/A?
The amendment adds Exhibit 10.3, a side letter dated June 30, 2026 between OS Therapies Incorporated and Leonite Fund I, LP. Other related transaction documents remain incorporated by reference from the original current report.
What other key agreements are referenced in the OS Therapies (OSTX) filing?
The exhibit list references a form of senior secured convertible promissory note, a form of common stock purchase warrant, a securities purchase agreement, a pledge and security agreement, and a related press release, all tied to the June 30, 2026 private placement.
Who signed the OS Therapies (OSTX) 8-K/A amendment?
The amendment was signed on behalf of OS Therapies Incorporated by Paul A. Romness, MPH, who is identified as the company’s President and Chief Executive Officer, acting as the duly authorized signatory under the Exchange Act.
What is the relationship between OS Therapies and Leonite Fund I, LP in this filing?
Leonite Fund I, LP is the counterparty in several private placement documents with OS Therapies, including the securities purchase agreement, pledge and security agreement, and the newly filed side letter that is now attached as Exhibit 10.3.